Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples